(Q37756167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Clinical experience with adalimumab in the treatment of ocular Behçet disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Ahmed Bawazeer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Lina H Raffa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

Ocular Immunology and Inflammation

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

226-232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Adalimumab: a new modality for Behçet's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Adalimumab: in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2010.483314

10.3109/09273948.2010.483314

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20482404%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference